Clinical criteria for a limbic‐predominant amnestic neurodegenerative syndrome highly associated with TDP‐43 and slow clinical progression

The implementation of LANS criteria has implications for disambiguating the different driving etiologies of progressive amnestic presentations in older age to guide prognosis, treatment, and clinical trial design and enrollment. The development of in vivo biomarkers specific to TDP-43 pathology are needed to further refine molecular associations between LANS and LATE-NC and precise antemortem diagnoses of LATE.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2024-12-01
DOI
https://doi.org/10.1002/alz.084087
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical criteria for a limbic‐predominant amnestic neurodegenerative syndrome highly associated with TDP‐43 and slow clinical progression

Val J. Lowe, Clifford R. Jack, Jonathan Graff‐Radford, Nikki H. Stricker et al.
Alzheimer s & Dementia
Alzheimer's disease research and treatments
article

Clinical criteria for a limbic‐predominant amnestic neurodegenerative syndrome highly associated with TDP‐43 and slow clinical progression

Val J. Lowe, Clifford R. Jack, Jonathan Graff‐Radford, Nikki H. Stricker, Michel J. Grothe, Dennis W. Dickson, Nick Corriveau‐Lecavalier, Peter T. Nelson, Scott A. Przybelski, Vijay K. Ramanan, Mary M. Machulda, Ronald Carl Petersen, Julie A. Fields, Melissa E. Murray, Hugo Botha, Stuart J. McCarter, Aivi T. Nguyen, David S. Knopman, David Thomas Jones, Bradley F. Boeve, Aaron Switzer, Ross R. Reichard, Heather J. Wiste
article en

Abstract

The implementation of LANS criteria has implications for disambiguating the different driving etiologies of progressive amnestic presentations in older age to guide prognosis, treatment, and clinical trial design and enrollment. The development of in vivo biomarkers specific to TDP-43 pathology are needed to further refine molecular associations between LANS and LATE-NC and precise antemortem diagnoses of LATE.

Alzheimer s & DementiaVol. 20(S3)
Mayo Clinic (US), University of Kentucky (US), German Center for Neurodegenerative Diseases (DE), WinnMed (US), Mayo Clinic in Arizona (US), Mayo Clinic in Florida (US)
Quality Education
Openalex Percentile: Top 65%
Alzheimer's disease research and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.